Zevra Therapeutics (ZVRA) Debt to Equity: 2014-2025
Historic Debt to Equity for Zevra Therapeutics (ZVRA) over the last 6 years, with Sep 2025 value amounting to $0.46.
- Zevra Therapeutics' Debt to Equity fell 45.47% to $0.46 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.46, marking a year-over-year decrease of 45.47%. This contributed to the annual value of $1.50 for FY2024, which is 117.00% up from last year.
- Per Zevra Therapeutics' latest filing, its Debt to Equity stood at $0.46 for Q3 2025, which was down 11.07% from $0.52 recorded in Q2 2025.
- Zevra Therapeutics' Debt to Equity's 5-year high stood at $1.80 during Q2 2024, with a 5-year trough of $0.01 in Q1 2021.
- Over the past 3 years, Zevra Therapeutics' median Debt to Equity value was $0.69 (recorded in 2023), while the average stood at $0.79.
- In the last 5 years, Zevra Therapeutics' Debt to Equity surged by 6,112.00% in 2024 and then crashed by 71.17% in 2025.
- Zevra Therapeutics' Debt to Equity (Quarterly) stood at $0.01 in 2021, then reached $0.17 in 2022, then skyrocketed by 305.70% to $0.69 in 2023, then soared by 117.00% to $1.50 in 2024, then tumbled by 45.47% to $0.46 in 2025.
- Its Debt to Equity was $0.46 in Q3 2025, compared to $0.52 in Q2 2025 and $1.46 in Q1 2025.